{"id":655000,"date":"2013-04-29T08:52:30","date_gmt":"2013-04-29T12:52:30","guid":{"rendered":"http:\/\/www.pehub.com\/?p=198845"},"modified":"2013-04-29T08:52:30","modified_gmt":"2013-04-29T12:52:30","slug":"gtcr-sells-actient","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/655000","title":{"rendered":"GTCR Sells Actient"},"content":{"rendered":"<p><strong>GTCR<\/strong> has sold <strong>Actient Holdings<\/strong> to <strong>Auxilium Pharmaceuticals<\/strong>. Financial terms were not announced. Lake Forest, Ill.-based Actient is a specialty pharmaceutical company focused on the treatment of urological indications. <strong>Jefferies<\/strong> served as Actient&#8217;s financial advisor.<\/p>\n<p>PRESS RELEASE<\/p>\n<p>GTCR, a leading private equity firm, announced today it has sold its portfolio company, Actient Holdings LLC (\u201cActient\u201d), to Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL, \u201cAuxilium\u201d), a specialty biopharmaceutical company.\u00a0 Headquartered in Lake Forest, Illinois, Actient is a specialty pharmaceutical company focused on developing, acquiring and marketing products that significantly improve patient outcomes.<\/p>\n<p>Actient was formed in March 2009 in partnership with GTCR.\u00a0 Through a series of five acquisitions, Actient built a diversified portfolio of commercial products and pipeline programs to create a unique specialty pharmaceutical company focused on the treatment of urological indications.<\/p>\n<p>\u201cOur partnership with Actient CEO Ed Fiorentino exemplifies GTCR\u2019s Leaders Strategy\u2122,\u201d said GTCR Managing Director Dean Mihas.\u00a0 \u201cWe created Actient with a strategy to build a leading specialty pharmaceutical company through the acquisition of companies and products.\u00a0 Through a series of transactions, Ed and the team have built a growing urology specialty company.\u00a0 The strategic acquisition of Actient is the culmination of this successful partnership and GTCR\u2019s healthcare strategy.\u201d Ben Daverman, GTCR Vice President, added, \u201cActient has been an excellent partnership for GTCR, and we are truly appreciative of the many fine efforts by Ed and his management team.\u201d<\/p>\n<p>\u201cI\u2019d like to thank GTCR for their efforts in helping Actient become a significant specialty company.\u201d said Mr. Fiorentino. \u201cWe have had a great partnership with GTCR and we look forward to working with Auxilium to continue Actient\u2019s efforts to develop products that significantly improve patient outcomes.\u201d<\/p>\n<p>Jefferies LLC served as Actient\u2019s financial advisor and Kirkland &amp; Ellis LLP provided legal counsel.<\/p>\n<p>About GTCR<br \/>\nFounded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services &amp; Technology, Healthcare and Information Services &amp; Technology industries. The Chicago-based firm pioneered The Leaders Strategy\u2122 &#8211; finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.<\/p>\n<p>About Actient Pharmaceuticals LLC<br \/>\nActient is a specialty products company focused on therapeutics to improve patient outcomes. The company was formed to acquire companies and products with a focus on select physician specialties. For more information, please visit www.actientpharma.com.<\/p>\n<p>The post <a href=\"http:\/\/www.pehub.com\/198845\/gtcr-sells-actient\/\">GTCR Sells Actient<\/a> appeared first on <a href=\"http:\/\/www.pehub.com\/\">peHUB<\/a>.<\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:dnMXMwOfBR0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=dnMXMwOfBR0\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?i=Uomwc4zp78Y:g11PUviwpKY:D7DqB2pKExk\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:7Q72WNTAKBA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=7Q72WNTAKBA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?i=Uomwc4zp78Y:g11PUviwpKY:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Uomwc4zp78Y:g11PUviwpKY:l6gmwiTKsz0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=l6gmwiTKsz0\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/pehub\/news\/all\/~4\/Uomwc4zp78Y\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GTCR has sold Actient Holdings to Auxilium Pharmaceuticals. Financial terms were not announced. Lake Forest, Ill.-based Actient is a specialty pharmaceutical company focused on the treatment of urological indications. Jefferies served as Actient&#8217;s financial advisor. PRESS RELEASE GTCR, a leading private equity firm, announced today it has sold its portfolio company, Actient Holdings LLC (\u201cActient\u201d), [&hellip;]<\/p>\n","protected":false},"author":7426,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-655000","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/655000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/7426"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=655000"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/655000\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=655000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=655000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=655000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}